Nucala

Nucala can only be obtained with a prescription and should be prescribed by a doctor experienced in identifying and treating severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, HES or EGPA.

The medicine is given by injection under the skin of the upper arm, thigh or abdomen (belly) once every 4 weeks. The recommended dose depends on the use and on the age of the patient. Nucala is intended for long-term treatment. The doctor should assess the need for continued treatment on an annual basis.

Nucala is available as a solution in a prefilled pen or syringe or as a powder that comes in a vial and is made up into an injection. The patient and carer can use the Nucala prefilled pen or syringe themselves once they have been trained, whereas the vial is only for use by a healthcare professional. For more information about using Nucala, see the package leaflet or contact your doctor or pharmacist.

In eosinophilic asthma, chronic rhinosinusitis with nasal polyps, EGPA and HES, symptoms are associated with having too many eosinophils in the blood and in phlegm in the lungs, nose and sinuses. The active substance in Nucala, mepolizumab, is a type of protein called a monoclonal antibody, which attaches to a specific substance in the body. Mepolizumab attaches to a substance called interleukin-5 that encourages the production and survival of eosinophils. By attaching to interleukin-5, mepolizumab blocks its action and thereby reduces the numbers of eosinophils. This helps to reduce inflammation, resulting in an improvement of symptoms.

Eosinophilic asthma

The benefits of Nucala in severe eosinophilic asthma that is not well controlled by previous treatment have been shown in three main studies, in which it was compared with a placebo (dummy) injection. The first study involved 616 adults and adolescents given Nucala every 4 weeks for a year, in addition to their regular asthma medicines. The second study involved 576 adults and adolescents given Nucala every 4 weeks for 28 weeks. The main measure of effectiveness in these studies was the number of severe attacks (exacerbations) of asthma that occurred during treatment, which was reduced by about half in patients given Nucala.

The third study involved 135 mostly adult patients with eosinophilic asthma severe enough to need regular treatment by mouth with corticosteroids, and the main measure of effectiveness was how much the corticosteroid dose could be reduced using Nucala for 24 weeks compared with placebo. Over half (37 of 69) of the patients given Nucala were able to reduce their daily corticosteroid dose by more than 50% to a dose of 5 mg or less, and 10 of them were able to stop corticosteroids altogether, compared with about a third of those given placebo (22 of 66, of whom 5 were able to stop corticosteroids).

An additional study was carried out in children aged 6 to 11 years which showed that a dose of 40 mg Nucala given under the skin produced comparable levels of active substance in the body to those seen with standard doses in adults. The reduction in eosinophil levels in the blood achieved in children was also comparable to that seen with standard doses in adults.

Severe chronic rhinosinusitis with nasal polyps

Nucala was studied in 407 patients with severe chronic rhinosinusitis with nasal polyps. The main measure of effectiveness was based on the size of the polyps measured by the nasal polyp score (score ranges from 0 to 8 (scored 0, no polyp to 4, large polyps)), as well as nasal obstruction measured by the symptom scoring system VAS (which ranges from 0 (no obstruction) to 10 (complete obstruction)). In patients treated with Nucala the nasal polyp score improved by 1.0 point after 52 weeks of treatment compared with 0 in those who received placebo. Nasal obstruction improved by 4.4 points with Nucala compared with 0.82 with placebo.

Eosinophilic granulomatosis with polyangiitis (EGPA)

Nucala was studied in 136 patients who received standard of care in addition to either Nucala or placebo. After 36 and 48 weeks of treatment 32% (22 out of 68) of patients treated with Nucala achieved remission (no signs and symptoms of vasculitis) compared with 3% (2 out of 68) of patients who received placebo.

Hypereosinophilic syndrome (HES)

A study in 108 patients showed that treatment with Nucala led to fewer flare-ups of the condition.  During treatment with either placebo or Nucala for 32 weeks, 15 out of 54 (28%) patients on Nucala had a flare-up, compared with 30 out of 54 (56%) patients on placebo.

The most common side effect with Nucala (which may affect more than 1 in 10 people) is headache. For the full list of side effects and restrictions with Nucala, see the package leaflet.

The European Medicines Agency decided that Nucala’s benefits are greater than its risks and it can be authorised for use in the EU. In adults the reduction seen in severe asthma attacks and consequent need for hospital treatment was considered important and outweighed the low risk of side effects. In addition, a reduction in corticosteroid dose was considered clinically relevant, given the potential complications of long-term corticosteroid treatment. In children, eosinophilic asthma is rare and the data available are therefore limited. The Agency concluded that the data available indicate that Nucala acts in a similar way in adults and children and the results in adults therefore also apply to children with eosinophilic asthma. Nucala was also shown to be beneficial with an acceptable safety profile in patients with chronic rhinosinusitis with nasal polyps, EGPA or HES and the Agency therefore recommended marketing authorisation.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nucala have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Nucala are continuously monitored. Side effects reported with Nucala are carefully evaluated and any necessary action taken to protect patients.

Nucala received a marketing authorisation valid throughout the EU on 2 December 2015.